GENOCEA BIOSCIENCES, INC. short interest in 2018
In 2018, GENOCEA BIOSCIENCES, INC.'s disclosed short interest ran from 5.75% of shares outstanding on 12 Jan 2018 to 2.30% on 31 Dec 2018, a change of -3.45 percentage points. The year's high was 20.15% on 30 Apr 2018 and its low 1.52% on 15 Aug 2018, averaging 6.28% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.08 days on 30 Nov 2018. Full history: GENOCEA BIOSCIENCES, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022
2018 in figures
- Start of year
- 5.75% (12 Jan 2018)
- End of year
- 2.30% (31 Dec 2018)
- Change
- -3.45 pp
- High
- 20.15% (30 Apr 2018)
- Low
- 1.52% (15 Aug 2018)
- Average
- 6.28%
- Highest days to cover
- 15.08 (30 Nov 2018)
- SEC filings marked
- 9
Every report in 2018
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2018 | 5.75% | 2.92 | |
| 31 Jan 2018 | 10.00% | 1.50 | results (8-K) |
| 15 Feb 2018 | 8.54% | 2.22 | results (8-K) |
| 28 Feb 2018 | 4.62% | 1.82 | 10-K filed |
| 15 Mar 2018 | 7.68% | 1.35 | |
| 29 Mar 2018 | 13.28% | 3.45 | |
| 13 Apr 2018 | 16.74% | 5.89 | |
| 30 Apr 2018 | 20.15% | 6.46 | |
| 15 May 2018 | 6.71% | 10.93 | results (8-K), 10-Q filed |
| 31 May 2018 | 5.17% | 10.24 | |
| 15 Jun 2018 | 7.10% | 10.48 | |
| 15 Aug 2018 | 1.52% | 3.83 | results (8-K), 10-Q filed |
| 31 Aug 2018 | 2.09% | 4.95 | |
| 14 Sep 2018 | 2.79% | 8.02 | |
| 28 Sep 2018 | 3.12% | 3.48 | |
| 15 Oct 2018 | 3.27% | 8.05 | |
| 31 Oct 2018 | 3.16% | 14.54 | |
| 15 Nov 2018 | 2.85% | 8.73 | 10-Q filed, results (8-K) |
| 30 Nov 2018 | 2.58% | 15.08 | |
| 14 Dec 2018 | 2.54% | 14.02 | |
| 31 Dec 2018 | 2.30% | 3.82 |
See also: GENOCEA BIOSCIENCES, INC.'s full history · most shorted US stocks of 2018 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.